Multiple Sclerosis
Conditions
Brief summary
In Multiple Sclerosis the multiplicity of physical and psychological dysfunctions have been shown to exhibit a number of life-altering problems such as fatigue, limb weakness, alteration of upper extremity fine motor coordination, loss of sensation, spasticity. These problems affect performance of many daily living activities (ADL) such as dressing, bathing, self-care, and writing, thus reducing functional independence and self-rated quality of life. Twenty people with Multiple Sclerosis will receive neurorehabilitation treatment comprising a combination of aerobic training and upper limb task-oriented training. The aim of this pilot crossover study is to evaluate the effects of neurorehabilitation on upper limb performance and on fatigue in People with Multiple Sclerosis.
Interventions
OTHERTask Oriented rehabilitation and aerobic training
Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
Sponsors
University of Genova
Fondazione Don Carlo Gnocchi Onlus
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Multiple Sclerosis * no relapses in the last three months * Expanded Disability Status Scale (EDSS) ≤ 8;
Exclusion criteria
* subjects with relapses * worsening of the pathology in the last three months * subjects with cognitive and psychiatric disturbances * subjects with cardiovascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in 9-hole peg test at 2 and 4 months | baseline, then participants were followed for the duration the outpatient treatment protocol, an average of 8 weeks, and at follow up 2 months after the end of the treatment protocol |
| Change from Baseline in Heart Rate at 2 and 4 months | baseline, then participants were followed for the duration the outpatient treatment protocol, an average of 8 weeks, and at follow up 2 months after the end of the treatment protocol |
Countries
Italy
Contacts
Primary ContactDavide Cattaneo, PhD
Outcome results
None listed